Impaired incretin-induced amplification of insulin secretion after glucose homeostatic dysregulation in healthy subjects

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Impaired incretin-induced amplification of insulin secretion after glucose homeostatic dysregulation in healthy subjects. / Hansen, Katrine B; Vilsbøll, Tina; Bagger, Jonatan I; Holst, Jens Juul; Knop, Filip K.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 97, No. 4, 2012, p. 1363-70.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Hansen, KB, Vilsbøll, T, Bagger, JI, Holst, JJ & Knop, FK 2012, 'Impaired incretin-induced amplification of insulin secretion after glucose homeostatic dysregulation in healthy subjects', Journal of Clinical Endocrinology and Metabolism, vol. 97, no. 4, pp. 1363-70. https://doi.org/10.1210/jc.2011-2594

APA

Hansen, K. B., Vilsbøll, T., Bagger, J. I., Holst, J. J., & Knop, F. K. (2012). Impaired incretin-induced amplification of insulin secretion after glucose homeostatic dysregulation in healthy subjects. Journal of Clinical Endocrinology and Metabolism, 97(4), 1363-70. https://doi.org/10.1210/jc.2011-2594

Vancouver

Hansen KB, Vilsbøll T, Bagger JI, Holst JJ, Knop FK. Impaired incretin-induced amplification of insulin secretion after glucose homeostatic dysregulation in healthy subjects. Journal of Clinical Endocrinology and Metabolism. 2012;97(4):1363-70. https://doi.org/10.1210/jc.2011-2594

Author

Hansen, Katrine B ; Vilsbøll, Tina ; Bagger, Jonatan I ; Holst, Jens Juul ; Knop, Filip K. / Impaired incretin-induced amplification of insulin secretion after glucose homeostatic dysregulation in healthy subjects. In: Journal of Clinical Endocrinology and Metabolism. 2012 ; Vol. 97, No. 4. pp. 1363-70.

Bibtex

@article{b2e5ce8c9af3424896df9aab15c075e2,
title = "Impaired incretin-induced amplification of insulin secretion after glucose homeostatic dysregulation in healthy subjects",
abstract = "The insulinotropic effect of the incretin hormones, glucose-dependent insulinotropic polypeptide (GIP), and glucagon-like peptide-1 (GLP-1) is impaired in patients with type 2 diabetes. It remains unclear whether this impairment is a primary pathophysiological trait or a consequence of developing diabetes. Therefore, we aimed to investigate the insulinotropic effect of GIP and GLP-1 compared with placebo before and after 12 d of glucose homeostatic dysregulation in healthy subjects.",
keywords = "Adult, Blood Glucose, C-Peptide, Gastric Inhibitory Polypeptide, Glucagon, Glucagon-Like Peptide 1, Glucose Clamp Technique, Glucose Intolerance, Glucose Tolerance Test, Humans, Incretins, Infusions, Intravenous, Insulin, Insulin Resistance, Insulin-Secreting Cells, Kinetics, Male, Severity of Illness Index, Young Adult",
author = "Hansen, {Katrine B} and Tina Vilsb{\o}ll and Bagger, {Jonatan I} and Holst, {Jens Juul} and Knop, {Filip K}",
year = "2012",
doi = "10.1210/jc.2011-2594",
language = "English",
volume = "97",
pages = "1363--70",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "Oxford University Press",
number = "4",

}

RIS

TY - JOUR

T1 - Impaired incretin-induced amplification of insulin secretion after glucose homeostatic dysregulation in healthy subjects

AU - Hansen, Katrine B

AU - Vilsbøll, Tina

AU - Bagger, Jonatan I

AU - Holst, Jens Juul

AU - Knop, Filip K

PY - 2012

Y1 - 2012

N2 - The insulinotropic effect of the incretin hormones, glucose-dependent insulinotropic polypeptide (GIP), and glucagon-like peptide-1 (GLP-1) is impaired in patients with type 2 diabetes. It remains unclear whether this impairment is a primary pathophysiological trait or a consequence of developing diabetes. Therefore, we aimed to investigate the insulinotropic effect of GIP and GLP-1 compared with placebo before and after 12 d of glucose homeostatic dysregulation in healthy subjects.

AB - The insulinotropic effect of the incretin hormones, glucose-dependent insulinotropic polypeptide (GIP), and glucagon-like peptide-1 (GLP-1) is impaired in patients with type 2 diabetes. It remains unclear whether this impairment is a primary pathophysiological trait or a consequence of developing diabetes. Therefore, we aimed to investigate the insulinotropic effect of GIP and GLP-1 compared with placebo before and after 12 d of glucose homeostatic dysregulation in healthy subjects.

KW - Adult

KW - Blood Glucose

KW - C-Peptide

KW - Gastric Inhibitory Polypeptide

KW - Glucagon

KW - Glucagon-Like Peptide 1

KW - Glucose Clamp Technique

KW - Glucose Intolerance

KW - Glucose Tolerance Test

KW - Humans

KW - Incretins

KW - Infusions, Intravenous

KW - Insulin

KW - Insulin Resistance

KW - Insulin-Secreting Cells

KW - Kinetics

KW - Male

KW - Severity of Illness Index

KW - Young Adult

U2 - 10.1210/jc.2011-2594

DO - 10.1210/jc.2011-2594

M3 - Journal article

C2 - 22319034

VL - 97

SP - 1363

EP - 1370

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 4

ER -

ID: 40379513